Hutchison China MediTech (AIM, NASDAQ:HCM) has initiated a U.S. Phase 1 bridging clinical trial of fruquintinib, a highly selective and potent oral inhibitor of vascular endothelial growth factor receptors 1, 2 and 3, that has met its primary endpoint in several Phase 2 and 3 clinical trials in China for the treatment of colorectal, lung and gastric cancers.Read More
Maxim Group raised its price target for BeiGene (NASDAQ:BGNE) to $120 from $77 after the company announced preliminary data from its ongoing Phase 1/2 study of BGB-A317 (PD-1 antibody) in Chinese patients with advanced solid tumors at the 20th annual meeting of the Chinese Society of Clinical Oncology in Xiamen, China.Read More
Closely-held Contextual Genomics has teamed up with CORE Diagnostics to introduce its Find-It genomic test in India.Read More
Analysts at Stifel and Leerink initiated coverage of Tocagen (NASDAQ:TOCA) with “buy” and “market perform” ratings, and price targets of $24 and $19, respectively. The stock closed at $17.40 on May 5.Read More
H.C. Wainwright raised its price target for Calithera Biosciences (NASDAQ:CALA) to $14 from $10, citing a recent partnership with Incyte and dilution from recent rounds of fund raising. The stock closed at $10.75 on March 28.Read More
Ladenburg Thalmann initiated coverage of Checkpoint Therapeutics (OTCQX:CKPT) with a “buy” rating and $20 price target. The stock closed at $13 on March 21.Read More
Ladenburg Thalmann launched coverage of Leap Therapeutics (NASDAQ: LPTX) with a “buy” rating and $18 price target. The stock closed at $7.85 on March 6.Read More
Closely-held Soricimed Biopharma announced publication in the peer-reviewed journal, Investigational New Drugs, The Journal of New Anticancer Agents of its first-in-human Phase 1 study of SOR-C13, a TRPV6 calcium channel inhibitor, in patients with advanced solid tumors.Read More
Roth Capital Partners has reinitiated coverage of Lion Biotechnologies (NASDAQ:LBIO) with a “buy” rating and $14 price target. The stock closed at $7.15 on Feb. 14.Read More
H.C. Wainwright initiated coverage of Calithera Biosciences (NASDAQ:CALA) with a “buy” rating and $9 price target. The stock closed at $3.95 on Jan. 5.Read More
Closely-held Soricimed Biopharma and collaborators plan to present four posters at the American Association of Cancer Research (AACR) annual meeting in New Orleans on April 16-20.
The presentations are based on preclinical and clinical research conducted on the company’s lead anti-cancer drug candidate, SOR-C13, a first-in-class inhibitor of the TRPV6 calcium channel.Read More
Closely-held Soricimed Biopharma has announced positive top-line results from a Phase 1 open-label, dose escalation study of its first-in-class peptide, SOR-C13, in subjects with advanced solid tumor cancers.
The primary goal of the study was to assess safety and tolerability of SOR-C13 in subjects with advanced carcinomas commonly known to express the TRPV6 channel and who had failed all previous anti-cancer treatments. SOR-C13 is the first drug candidate targeting TRPV6 to enter human clinical trials.Read More